Neutrophil gelatinase-associated lipocalin in blood in children with inflammatory bowel disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 11, 2014, Pages 1883-1889

  Janas, Roman M ^a   Ochocińska, Agnieszka ^a   Śnitko, Rafał ^a   Dudka, Dorota ^a   Kierkuś, Jarosław ^a   Teisseyre, Mikołaj ^a   Najberg, Ewa ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Allergy; Biomarkers; Neutrophil gelatinase associated lipocalin; Pediatric inflammatory bowel disease

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ADOLESCENT; AGE; BLOOD; CHILD; FEMALE; HUMAN; INFANT; INFLAMMATORY BOWEL DISEASES; MALE; PRESCHOOL CHILD;

ACUTE-PHASE PROTEINS; ADOLESCENT; AGE FACTORS; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; LIPOCALINS; MALE; PROTO-ONCOGENE PROTEINS;

EID: 84912003995     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12597     Document Type: Article

References (39)

1. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993; 268: 10425-10432.
2. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinsase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J. Biol. Chem. 2001; 276: 37258-37265.
3. Chakraborty S, Kuar S, Guha S, Batra SK. The multifaceted roles of neutrophil gelatinase-associated lipocalin (NGAL) in inflammation and cancer. Biochim. Biophys. Acta 2012; 1826: 129-169.
4. Singer E, Markó L, Paragas N etal. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol. 2013; 207: 6063-6672.
5. Liu Q, Nilsen-Hamilton M. Identification of a new acute phase protein. J. Biol. Chem. 1995; 270: 22565-22570.
6. Cowland JB, Sorensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J. Immunol. 2003; 171: 6630-6639.
7. Schmidt-Ott KM, Mori K, Li JY etal. Dual action of neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2007; 18: 407-413.
8. Yan QW, Yang Q, Mody N etal. The adipokine lipocalin 2 is regulated by obesity and promotes insulin resistance. Diabetes 2007; 56: 2533-2540.
9. Mucha M, Skrzypiec AE, Schiavon E, Attwood BK, Kucerova E, Pawlak R. Lipocalin-2 controls neuronal excitability and anxiety by regulating dendritic spine formation and maturation. Proc. Natl. Acad. Sci. U. S. A. 2011; 108: 18436-18441.
10. Pedersen KR, Ravn HB, Hjortdal VE, Nørregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand. J. Clin. Lab. Invest. 2010; 70: 374-382.
11. Schmidt-Ott KM. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury-where do we stand today? Nephrol. Dial. Transplant. 2011; 26: 762-764.
12. Virzi GM, Clementi A, Decal M, Cruz DN, Ronco C. Genomics and biological activity of neutrophil gelatinase-associated lipocalin in several clinical settings. Blood Purif. 2013; 35: 139-143.
13. Yang J, Goetz D, Li JY etal. An iron delivery pathway mediated by a lipocalin. Mol. Cell 2002; 10: 1045-1056.
14. Bao G, Clifton M, Hoette TM etal. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat. Chem. Biol. 2010; 6: 602-609.
15. Fischbach MA, Lin H, Liu DR, Walsch CT. How pathogenic bacteria evade mammalian sabotage in the battle for iron. Nat. Chem. Biol. 2006; 2: 132-138.
16. Mishra J, Ma Q, Prado A etal. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003; 14: 2534-2543.
17. Mishra J, Dent C, Tarabishi R etal. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005; 365: 1231-1238.
18. Viau A, El KK, Laouari D etal. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Invest. 2010; 120: 4065-4067.
19. Tomonaga Y, Szucs T, Ambühl P, Nock S, Risch M, Risch L. Insights on urinary NGAL obtained in a primary care setting. Clin. Chim. Acta 2012; 413: 733-739.
20. Cernaro V, Bolignano D, Donato V etal. NGAL is a precocious marker of therapeutic response. Curr. Pharm. Des. 2011; 17: 844-849.
21. Bennett MR, Piyaphanee N, Czech K, Mitsnefes M, Devarajan P. NGAL distinguishes steroid sensitivity in idiopathic nephrotic syndrome. Pediatr. Nephrol. 2012; 27: 807-812.
22. Akelma AZ, Abaci A, Ozdemir O etal. The association of serum lipocalin-2 levels with metabolic and clinical parameters in obese children: a pilot study. J. Pediatr. Endocrinol. Metab. 2012; 25: 525-528.
23. Catalán V, Gómez-Ambrosi J, Rodríguez A etal. Increased adipose tissue expression of lipocalin-2 in obesity is related to inflammation and matrix metalloproteinase-2 and metalloproteinase-9 activities in humans. J. Mol. Med. 2009; 87: 803-813.
24. Thrailkill KM, Moreau CS, Cockrell GE etal. Disease and gender-specific dysregulation of NGAL and MMP-9 in type-1 diabetes mellitus. Endocrine 2010; 37: 336-343.
25. Wang Y, Lam KS, Kraegen EW etal. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin. Chem. 2007; 53: 34-41.
26. Li C, Chan YR. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine 2011; 56: 435-441.
27. Nielsen OH, Gionchetti P, Ainsworth M etal. Rectal dialysate and fecal concentration of neutrophil gelatinase-associated lipocalin, interleukin-8 and tumor necrosis factor-α in ulcerative colitis. Am. J. Gastroenterol. 1999; 94: 2923-2928.
28. Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M. Neutrophil gelatinase-associated lipocalin levels in patients with Crohn's disease undergoing treatment with infliximab. J. Invest. Med. 2010; 58: 569-571.
29. Chassaing B, Srinivasan G, Delgado MA, Young AN, Gerwitz AT, Vijay-Kumar M. Fecal lipocalin-2, a sensitive and broadly dynamic non-invasive biomarker for intestinal inflammation. PLoS ONE 2012; 7: e66328. Cited 5 Sep 2012. Available from URL: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0044328
30. Cayatte C, Joyce-Shaikh B, Vega F etal. Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease. Clin. Transl. Gastroenterol. 2012; 3: e10. Cited 16 Feb 2012. Available from URL: http://www.nature.com/ctg/journal/v3/n2/full/ctg20122a.html
31. Oikonomou KA, Kapsoritakis AN, Theodoridau C etal. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology and inflammation, established markers, and disease activity. J. Gastroenterol. 2012; 47: 519-530.
32. Yeşil A, Gönen C, Senateş E etal. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig. Dis. Sci. 2013; 58: 2587-2593.
33. Levis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140: 1817-1826.
34. Manfredi MA, Zurakowski D, Rufo PA, Walker TR, Fox VL, Moses MA. Increased incidence of urinary matrix metalloproteinases as predictors of disease in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 2008; 14: 1091-1096.
35. Kofla-Dlubacz A, Matusiewicz M, Krzystek-Korpacka M, Iwanczak D. Correlation of MMP-3 and MMP-9 with Crohn's disease activity in children. Dig. Dis. Sci. 2012; 57: 706-712.
36. Ostafin A, Śnitko R, Dudka D etal. Serum neutrophil gelatinase-associated lipocalin (NGAL) concentration is highly elevated in children with inflammatory bowel disease [Abstract]. Falk Symp. 2011; (Abstract Book): 179: 45.
37. Ochocińska A, Dudka D, Śnitko R etal. Further studies on the serum neutrophil-gelatinase-associated lipocalin-2 (NGAL) in children with inflammatory bowel disease (IBD) [Abstract]. Falk Symp. 2012; (Abstract Book): 183: 49.
38. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory bowel disease in children and adolescents: recommendations for diagnosis-the Porto Criteria. J. Pediatr. Gastroenterol. Nutr. 2005; 41: 1-7.
39. Bangert K, Rosenkilde N, Jørgensen JP, Baer A, Utlenthal LO. Immunochemical determination of monomer, homodimer and total neutrophil gelatinase-associated lipocalin [Abstract]. J. Am. Soc. Nephrol. 2012; 23 (Suppl.): SA-PO820.